Fox Run Management’s Amicus Therapeutics FOLD Stock Holding History

Fox Run Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-70,115	Closed	-$553K	–	1021
2025 Q3	$553K	Buy	+70,115	New	+$499K	0.09%	454
2025 Q2	–	Sell	-21,449	Closed	-$175K	–	986
2025 Q1	$175K	Sell	21,449 -41,121	-66%	-$381K	0.03%	816
2024 Q4	$589K	Buy	62,570 +30,162	+93%	+$314K	0.11%	381
2024 Q3	$346K	Buy	+32,408	New	+$353K	0.08%	493
2023 Q1	–	Sell	-12,262	Closed	-$150K	–	751
2022 Q4	$150K	Sell	12,262 -373	-3%	-$4.2K	0.06%	524
2022 Q3	$132K	Buy	+12,635	New	+$141K	0.05%	528
2021 Q4	–	Sell	-27,620	Closed	-$264K	–	553
2021 Q3	$264K	Buy	+27,620	New	+$283K	0.17%	276
2019 Q3	–	Sell	-16,343	Closed	-$204K	–	436
2019 Q2	$204K	Buy	+16,343	New	+$207K	0.14%	367
2018 Q4	–	Sell	-12,156	Closed	-$147K	–	585
2018 Q3	$147K	Sell	12,156 -8,225	-40%	-$115K	0.06%	503
2018 Q2	$318K	Buy	+20,381	New	+$308K	0.1%	408

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fox Run Management's FOLD Position: Q4 2025 in Review

Fox Run Management sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 70,115 shares — an estimated $553K sold.

Fox Run Management first reported a position in FOLD in Q2 2018 and held it in 10 quarters. The position peaked at $589K in Q4 2024. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

Fox Run Management reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
Fox Run Management sold 70,115 Amicus Therapeutics shares in Q4 2025, an estimated $553K.
Fox Run Management first reported a position in Amicus Therapeutics in Q2 2018 and held it in 10 quarters.
Fox Run Management's Amicus Therapeutics position peaked at $589K in Q4 2024.
332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.